This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): cyclosporine (opthalmic emulsion)
Description: Cyclosporine is an immunosuppressive agent when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, cyclosporine emulsion is thought to act as a partial immunomodulator. Cyclosporine is a powerful immunosuppressant that has had a significant impact on transplant medicine. It inactivates T cells by inhibiting calcineurin phosphatase activity resulting in the inhibition of the transcription factor nuclear factor of activated T cells (NFAT).
Inspire and Allergan
In June 2001, Inspire Pharmaceuticals entered into a joint license, development and marketingagreement with Allergan to develop and commercialize two novel therapeutic treatments for dry eye, INS365 Ophthalmic and Restasis. Under the terms of the agreement, Allergan obtained an exclusive license to develop andcommercialize INS365 Ophthalmic worldwide, with the exception of Japan and nine other Asian countries covered by Inspire's agreementwith Santen. In return, Inspire will receive up to $39 million in up-front and milestone payments, a co-promotion option for INS365 Ophthalmic in the United States and royalty payments based on net sales. In addition, Inspire can receive royalties on global net sales of Allergan's Restasis, excluding sales inJapan, Taiwan, Korea, Hong Kong and Peoples Republic of China markets. The agreement also provides for potential co-promotion by Inspire of INS365 Ophthalmic and Restasis and one or more of Allergan's other...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc.
Additional information available to subscribers only: